Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
Capetti A, Meraviglia P, Landonio S, Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B, De Socio GV, Franzetti M, Soria A, Meschiari M, Sasset L, Pellicanò G, Mazzotta E, Trezzi M, Celesia BM, Melzi S, Carenzi L, Ricci E, Rizzardini G. Capetti A, et al. Among authors: melzi s. Int J Antimicrob Agents. 2014 Feb;43(2):189-94. doi: 10.1016/j.ijantimicag.2013.10.013. Epub 2013 Nov 15. Int J Antimicrob Agents. 2014. PMID: 24315315
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
Capetti A, Landonio S, Meraviglia P, Di Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B, Franzetti M, De Socio GV, Pellicanò G, Mazzotta E, Soria A, Meschiari M, Trezzi M, Sasset L, Celesia BM, Zucchi P, Melzi S, Ricci E, Rizzardini G. Capetti A, et al. Among authors: melzi s. PLoS One. 2012;7(7):e39222. doi: 10.1371/journal.pone.0039222. Epub 2012 Jul 11. PLoS One. 2012. PMID: 22808029 Free PMC article.
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rossella E, Palvarini L, Marconi P, Melzi S, Mura MS, Bonfanti P; Gruppo CISAI. Madeddu G, et al. Among authors: melzi s. Infez Med. 2006 Sep;14(3):125-34. Infez Med. 2006. PMID: 17127826 Free article. Review. Italian.
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T; CISAI Group. Madeddu G, et al. Among authors: melzi s. Biomed Pharmacother. 2008 Jan;62(1):6-11. doi: 10.1016/j.biopha.2007.04.008. Epub 2007 May 29. Biomed Pharmacother. 2008. PMID: 17574807
Treatment-related factors and highly active antiretroviral therapy adherence.
Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, Mura MS, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Trotta MP, et al. Among authors: melzi s. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S128-31. doi: 10.1097/00126334-200212153-00008. J Acquir Immune Defic Syndr. 2002. PMID: 12562035 Review.
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, Hoetelmans R, Murri R, Melzi S, Narciso P, Nasta P, Zaccarelli M, Santopadre P, Vecchiet J, Izzo CM, Maonforte Ad; AdICoNA Study Group. Antinori A, et al. Among authors: melzi s. Antivir Ther. 2004 Apr;9(2):291-6. Antivir Ther. 2004. PMID: 15134192 Clinical Trial.
49 results